Merck: Aiming for Health Equity and Business Success

Josette Gbemudu is motivated to ensure everyone has the chance to be as healthy as possible

As an executive director of health equity and social determinants of health for Merck, Gbemudu draws on her health policy and public health backgrounds - and her strong moral compass and lived experience.

"I grew up in Nigeria and witnessed the health care and public health system crumble," she said. "Populations that were already underserved faced even further barriers to care."

She takes pride in giving a voice to those who may not traditionally have had a seat at the table.

"The work we do is very exciting and important - it's challenging, it's not easy, there's a lot you have to do to navigate - but it's all fulfilling," she said.

A ‘first mover'

Gbemudu is the first person from Merck to participate in the Aspen Institute's First Movers Fellowship program.

The program equips leaders across industries to be intrapreneurs, meaning they work to advance societal value while also positioning their companies for sustained success.

"The global community is increasingly asking, and frankly, requiring, organizations to have a clear position around what they are doing to tackle the world's most pressing and imminent challenges."
- Josette Gbemudu

"This fellowship has provided a tremendous opportunity to home in on what it takes to be a corporate social intrapreneur, and how to incorporate that intrapreneurial drive and mentality into my day-to-day," Gbemudu said.

At the nexus of health equity

Fellows are challenged to lead change and create new opportunities within their business to help redefine how business is done and how success is measured. At Merck, Gbemudu and her colleagues are developing and implementing company-wide strategies to help close gaps in care for underserved populations.

"It's fantastic to be at the nexus of the efforts to embed a health equity mindset across our core business strategies and functions," Gbemudu said. "Big problems won't be solved overnight. But historically, we've risen to the challenge in addressing a lot of pressing public health issues. It's interwoven into our DNA."

Learn more about Merck's Environmental, Social & Governance (ESG) approach by visiting merck.com/company-overview/esg.

View original content here.

View additional multimedia and more ESG storytelling from Merck & Co., Inc. on 3blmedia.com.

Contact Info:
Spokesperson: Merck & Co., Inc.
Website: https://www.3blmedia.com/profiles/merck-co-inc
Email: info@3blmedia.com

SOURCE: Merck & Co., Inc.



View source version on accesswire.com:
https://www.accesswire.com/748014/Merck-Aiming-for-Health-Equity-and-Business-Success

News Provided by ACCESSWIRE via QuoteMedia

MRK
The Conversation (0)
Merck Announces First-Quarter 2023 Financial Results

Merck Announces First-Quarter 2023 Financial Results

First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines Total Worldwide Sales Were $14.5 Billion, a Decrease of 9% From First Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of... Keep Reading...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847. There is no cost or financial obligation to you.... Keep Reading...
OTC:BCTXF

BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health

Highlights: Grant awarded to Dr. Saveri Bhattacharya, Principal Investigator of the Phase I/IIa combination study of Bria-IMT™ with KEYTRUDA® (by Merck) in advanced breast cancer at Thomas Jefferson University. Merck to provide KEYTRUDA® for use in the combination study. The Investigator Grant... Keep Reading...

Merck Announces Q4 and Full-Year 2019 Financial Results

Merck (NYSE:MRK) reported quarterly worldwide sales at US$11.9 billion in Q4 in its financial results for the fourth quarter of 2019 and its full fiscal 2019 year. As quoted in the press release: As evidenced by our results and our 2020 guidance, Merck had an extraordinary year and is in a... Keep Reading...
OTC:BCTXF

BriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston

Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: Bria-IMT™ in combination with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.); Bria-IMT™ in combination with INCMGA00012 (by Incyte... Keep Reading...
Thian Chew, CEO of Invion

Invion Advances Global Strategy With New Licencing Agreement

Invion (ASX:IVX) has taken a major step forward with a new global licencing agreement that streamlines its rights across key cancer and infectious disease programs. The move gives the company a clearer path to advance its Photosoft technology, expand market opportunities and strengthen... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market is set to surpass a total value of US$1.75 trillion by the end of the decade, according to Evaluate Pharma.Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma... Keep Reading...
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company... Keep Reading...
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

4 Best-performing Canadian Pharma Stocks of 2025

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are... Keep Reading...
 Thian Chew, CEO of Invion

New Deal Could Spark Invion’s Entry into Pet Cancer Market, CEO Says

Invion’s (ASX:IVX,OTC Pink:IVIXF) Photosoft cancer treatment technology has entered an important milestone, thanks to a new collaboration deal with Taiwanese firm Protect Animal Health, to undertake studies to treat cancer in pets.“The significance of this recent collaboration is (that) now... Keep Reading...

Latest Press Releases

Related News